

Special Issue

Genetics and Treatment of Dilated Cardiomyopathy

Message from the Guest Editor

JCDD launches a Special Issue on “Genetics and Treatment of Dilated Cardiomyopathy”. Idiopathic dilated cardiomyopathy (DCM) is a heritable, progressive disorder that ultimately leads to heart failure. The identification of many causative genes and key pathological pathways opens the door to new therapeutic strategies. However, the development of effective therapy is significantly hindered by the heterogeneous nature of DCM, manifesting as both locus heterogeneity and phenotypic variation. Therefore, strategies that enable the categorization of DCM into different types and development of individualized medicine tailored for different DCM types are needed. The advent of genomic tools and the integration of in vitro and in vivo models offer new research opportunities to identify the remaining causative genes, to pinpoint underlying mechanisms and to identify effective therapies.

Guest Editor

Prof. Dr. Xiaolei Xu

Department of Biochemistry and Molecular Biology, and Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905, USA

Deadline for manuscript submissions

closed (30 June 2017)



Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/8490

*Journal of Cardiovascular
Development and Disease*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcdd@mdpi.com

[mdpi.com/journal/
jcdd](http://mdpi.com/journal/jcdd)





Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)



About the Journal

Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease* (JCDD, ISSN 2308-3425) is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to *JCDD* undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. *JCDD* guarantees fast dissemination of results to a large scientific audience.

Editor-in-Chief

Prof. Dr. Thomas Brand
National Heart & Lung Institute, Imperial College London, South
Kensington Campus, London SW7 2AZ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) /
CiteScore - Q2 (General Pharmacology, Toxicology and
Pharmaceutics)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 24.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).